Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

Cancer

Volumn 97, Issue 6, 2003, Pages 1481-1487

  Tsimberidou, Apostolia ^a   Estey, Elihu ^a   Cortes, Jorge ^a   Thomas, Deborah ^a   Faderl, Stefan ^a   Verstovsek, Srdan ^a   Garcia Manero, Guillermo ^a   Keating, Michael ^a   Albitar, Maher ^a   O'Brien, Susan ^a   Kantarjian, Hagop ^a   Giles, Francis ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myelogenous leukemia; Cyclosporine; Cytarabine; Fludarabine; Gemtuzumab (Mylotarg ); Venoocclusive disease

Indexed keywords

AMPHOTERICIN B; CYCLOSPORIN; CYTARABINE; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; ITRACONAZOLE; LEVOFLOXACIN; METHYLPREDNISOLONE; URSODEOXYCHOLIC ACID; VERAPAMIL;

ABDOMINAL DISTENSION; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; ASCITES; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; INTESTINE OBSTRUCTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; SEPSIS; SIDE EFFECT; SURVIVAL RATE; VEIN OCCLUSION; WEIGHT GAIN;

ADULT; AGED; ALANINE TRANSAMINASE; AMINOGLYCOSIDES; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; CYCLOSPORINE; CYTARABINE; FEMALE; HUMANS; HYPERBILIRUBINEMIA; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME; VIDARABINE;

EID: 19244365993     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11239     Document Type: Article

References (30)

1. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
2. Bernstein ID. CD33 as a target for selective ablation of acute myeloid leukemia. Clin Lymphoma. 2002;2(Suppll):S9-S11.
3. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002;99:4343-4349.
4. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
5. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92:406-413.
6. Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H, Estey E. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica. 2002;87:1114-1116.
7. Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001;98:3575-3583.
8. Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999;93: 2478-2484.
9. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993;9:343-350.
10. Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98:988-994.
11. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98:3212-3220.
12. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
13. Bearman SI. Veno-occlusive disease of the liver. Curr Opin Oncol. 2000;12:103-109.
14. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94:1086-1099.
15. Young IT. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem. 1977;25:935-941.
16. McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma. 2002;2 (Suppl 1):S35-39.
17. Tack DK, Letendre L, Kamath PS, Tefferi A. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant. 2001;28:811-812.
18. Langston A, Fienstein B, Hutcherson D, et al. Non-fatal veno-occlusive disease in non-transplant patients after treatment of relapsed AML with Mylotarg (gemtuzumab ozogamicin) [abstract]. Blood. 2001;98:201b.
19. Lech JA, Rossetti J, Lister J, et al. Hepatic venoocclusive disease as a complication of Mylotarg (gemtuzumab ozogamicin): The Western Pennsylvania Cancer Institute experience [abstract]. Blood. 2001;98:202b.
20. Kell JW, Burnett AK, Chopra R, Yin J. Effects of Mylotarg (gemtuzumab ozogomycin) in combination with standard induction chemotherapy in the treatment of acute myeloid leukaemia: a feasibility study [abstract]. Blood. 2001;98:123a.
21. Amadori S, Willemze R, Suciu S, et al. Sequential administration of gemtuzumab ozogamicin and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: interim results of the EORTC leukemia group AML - a phase II trial [abstract]. Blood. 2001;98:587a.
22. Sievers EL, Larson RA, Estey E, et al. Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676): relationship to hematopoietic stem cell transplantation [abstract]. Blood. 2000;96:206b.
23. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:2310-2314.
24. Tsimberidou A, Estey E, Cortes J, et al. Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. In press.
25. Tsimberidou A, Cortes J, Thomas D, et al. Mylotarg, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33-positive primary resistant of relapsed acute myeloid leukemia. Leukemia Res. In press.
26. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood. 2000;95:72-77.
27. Estey EH, Keating MJ, Dixon DO, Trujillo JM, McCredie KB, Freireich EJ. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia. Hematol Pathol. 1987;1:203-208.
28. Albitar M. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol. 2001;106:170-176.
29. Albitar M, Manshouri T, Shen Y, et al. Myelodysplastic syndrome is not merely "preleukemia". Blood. 2002;100:791-798.
30. Jilani I, Estey E, Huh Y, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002; 118:560-566.